Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials
Schizophrenia Bulletin · 01.01.2024 · 50 (1) · 132-144
DOI: 10.1093/schbul/sbad089 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Schizophrenia Bulletin, online erschienen am 23.06.2023. Verfasst von Dongfang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, German Research Foundation.
Abstract (Originalsprache)
Background and Hypothesis Long-acting injectable antipsychotic drugs (LAIs) are mainly used for relapse prevention but could also be advantageous for acutely ill patients with schizophrenia. Study Design We conducted a systematic review and meta-analysis of randomized-controlled-trials (RCTs) comparing the second-generation long-acting injectable antipsychotics (SGA-LAIs) olanzapine, risperidone, paliperidone, and aripiprazole with placebo or their oral counterparts in acutely ill patients with schizophrenia. We analyzed 23 efficacy and tolerability outcomes, with the primary outcome being overall symptoms of schizophrenia. The results were obtained through random effects, pairwise meta-analyses, and subgroup tests. The study quality was assessed using the Cochrane-Risk-of-Bias-Tool version-1. Study Results Sixty-six studies with 16 457 participants were included in the analysis. Eleven studies compared second-generation long-acting injectable antipsychotics (SGA-LAIs) with a placebo, 54 compared second-generation oral antipsychotics (SGA-orals) with a placebo, and one compared an SGA-LAI (aripiprazole) with its oral formulation. All 4 SGA-LAIs reduced overall symptoms more than placebo, with mean standardized differences of −0.66 (95% CI: −0.90; −0.43) for olanzapine, −0.64 (−0.80; −0.48) for aripiprazole, −0.62 (−0.76; −0.48) for risperidone and −0.42 (−0.53; −0.31) for paliperidone. The side-effect profiles of the LAIs corresponded to the patterns known from the oral formulations. In subgroup tests compared to placebo, some side effects were less pronounced under LAIs than under their oral formulations. Conclusions SGA-LAIs effectively treat acute schizophrenia. Some side effects may be less frequent than under oral drugs, but due to the indirect nature of the comparisons, this finding must be confirmed by RCTs comparing LAIs and orals head-to-head.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany.
- Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA and Maryland Psychiatric Research Center, Baltimore, MD, USA.
ORCID-Profile: Stefan Leucht
Förderung
- National Natural Science Foundation of China
- German Research Foundation
Zitieren
APA
Wang, D., Schneider-Thoma, J., Siafis, S., Burschinski, A., Dong, S., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024). Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. Schizophrenia Bulletin, 50(1), 132-144. https://doi.org/10.1093/schbul/sbad089
Vancouver
Wang D, Schneider-Thoma J, Siafis S, Burschinski A, Dong S, Wu H, et al. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. Schizophrenia Bulletin. 2024;50(1):132-144. doi:10.1093/schbul/sbad089
BibTeX
@article{Wang2024,
author = {Wang, Dongfang and Schneider-Thoma, Johannes and Siafis, Spyridon and Burschinski, Angelika and Dong, Shimeng and Wu, Hui and Zhu, Yikang and Davis, John M and Priller, Josef and Leucht, Stefan},
title = {Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials},
journal = {Schizophrenia Bulletin},
year = {2024},
volume = {50},
number = {1},
pages = {132--144},
doi = {10.1093/schbul/sbad089}
}
EUVIMED